News

With the pending decision on 2 more CGRP agents, the need for biomarkers to identify responders has never been greater.

Goadsby spoke about differentiating between the foursome of preventive therapies soon to be available to physicians.

The Saunders Family Professor of Neurology and the director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis at Mount Sinai Medical Center discussed the need for biomarkers in MS.

Thomas Berk, MD, discussed the current therapeutic landscape of migraine, emphasizing the importance of conversing with each patient to identify an individualized approach.

David Dodick, MD, a neurologist at Mayo Clinic who’s been involved with multiple trials of headache medicines, provided further insight into the medication class.

A meta-analysis revealed a history of stroke increases dementia risk by around 70%, and recent strokes more than doubled the risk.

The neurologist at the Mellen Center for Multiple Sclerosis at Cleveland Clinic touched on the therapy’s performance in a phase II clinical trial.

Despite supportive preclinical data, no evidence showed that dextroamphetamine in combination with physiotherapy leads to improvement in post-stroke recovery.

Jeffrey Allen, MD, spoke about the breakthrough barrier in CIDP and the importance of the guidelines for diagnosis.

The small molecule slowed atrophy by roughly 2.5 mL less brain-tissue loss compared to placebo.

Results provide Class IV evidence that nusinersen is safe and efficient on motor symptoms in patients older than 7 months of age.

Data suggest that nationally representative readmission metrics be used to benchmark hospital’s performance.

Perceptive neurologists have discovered a new type of vertigo. So far, the cause is unknown, though treatment seems to be effective.

What are the best available options for patients with CIDP, and what is still missing?

The Director of the Movement Disorders Clinic at the University of Louisville emphasized the importance of knowing each patient, where they’re coming from and their goals.

A subcutaneous intrathecal catheter delivery system has proven safe and tolerable in a preliminary investigation in patients with SMA.

The director of the ALS Clinic at Massachusetts General Hospital pointed to the robust pipeline and meaningful gains in knowledge about the disease as reason to be hopeful.

The director of the Movement Disorders Clinic at University of Louisville spoke about current therapies available for patients but stressed that they often don’t address the non-motor features.

The director of the Pediatric Headache Program at the Children’s Hospital of Philadelphia said that for these patients, there are still many questions without answers.

How did erenumab's approval by the FDA change the landscape of migraine treatment?

The VMAT2 inhibitor showed improvements through 48 weeks, though after halting therapy, some loss of improvement was observed.

If granted approval, DTHR-ALZ would be the first non-pharmacological prescription treatment to mitigate agitation and depression associated with Alzheimer disease.

The director of the Pediatric Headache Program at Children’s Hospital of Philadelphia spoke about the potential for CGRP inhibitors to find use in pediatric patients.

The COMT inhibitor resulted in 65-minute and 39-minute decreases in mean off time for patients who switched from placebo and entacapone, respectively.

Can this first-of-its-kind guideline for identifying biomarkers in Parkinson disease invigorate a drive for disease-modifying therapy development?

Results concluded that noninvasive OCT was able to detect significant thinning especially in the center of the retina, around the fovea, in the inner layers of the retina prior to any evidence of dementia.

The mesenchymal stem cell therapy passed an interim safety analysis for the first 31 patients with amyotrophic lateral sclerosis.

The Clinical Director of the Brain Donation Program at Cleveland Clinic’s Mellen Center for Treatment and Research in MS provided some insight into the consequences of this discovery.

After identifying and reviewing 76 randomized trials, combination therapy with memantine and AChEIs is confirmed to have no additional benefits over monotherapy.

Lutz Frölich, MD, PhD, provides a look at BI409306, a novel selective PDE9A inhibitor, and how the negative results of its phase II trial can inform the community.